Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Michael Walter

Michael Walter
Managing Editor


Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

LATEST ARTICLES BY THIS AUTHOR

TAVR still a safe option for patients with nickel allergies
Why patient selection is so important when performing M-TEER
FDA clears single-use, fully disposable endovascular robotic system
Q&A: Cardiologist explores CMS proposal to cover cardiac ablations performed in ambulatory surgical centers
Update: FDA announces new Class I recalls due to safety issue with Medtronic catheters
Seeing is believing: New cath lab technology takes coronary stent visualization to the next level
Medtronic’s RDN system approved in Japan
Drug-coated balloons make little impact on PAD outcomes
Johnson & Johnson’s PFA platform is both safe and effective, real-world data confirm
Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …46
    • Page 47
    • Page 48
    • Page 49
    • Current page 50
    • Page 51
    • Page 52
    • Page 53
    • Page 54 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme